In addition, the subgroup of ALK+ ALCL boasts a unique phenotype in which PD-L1 expression was detected at high rates in the tumor and microenvironment of these lymphomas, although this has not yet been correlated to response rates to PD-1/PD-L1 targeting agents (176). This evidence concerns the gene ALK and neoplasm.